| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.070 | Biomarker | group | BEFREE | However, compared to the large amount of clinical studies with JAK inhibitors that are currently widely used in the clinics to treat myeloproliferative disorders, the clinical trials with STAT5 inhibitors are very limited. | 31490767 | 2019 | ||||
|
0.070 | Biomarker | group | BEFREE | We found that homozygous Stat5 deficiency extended the lifespan of Nf1-deficient mice and eliminated the development of myeloproliferative neoplasm associated with Nf1 gene loss. | 27418650 | 2016 | ||||
|
0.070 | GeneticVariation | group | BEFREE | Hemopoietic progenitor cells (HPC) from myeloproliferative neoplasms (MPN) such as myelofibrosis commonly express mutant JAK2-V617F or other mutations that are associated with increased activities of JAK-STAT5/3, RAS/RAF/MAPK, and PI3K/AKT/mTOR pathways. | 23445613 | 2013 | ||||
|
0.070 | Biomarker | group | BEFREE | STAT5 proteins are constitutively activated in malignant cells from many patients with leukemia, including the myeloproliferative neoplasms (MPNs) chronic myeloid leukemia (CML) and polycythemia vera (PV), but whether STAT5 is essential for the pathogenesis of these diseases is not known. | 22234689 | 2012 | ||||
|
0.070 | AlteredExpression | group | BEFREE | Eliminating STAT5 expression had dramatic effects in both contexts, and this new work and other recent studies support the therapeutic potential of targeting pathways regulated by this important signaling molecule in patients with myeloproliferative neoplasms (MPNs). | 22500049 | 2012 | ||||
|
0.070 | PosttranslationalModification | group | BEFREE | The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis. | 21749449 | 2011 | ||||
|
0.070 | GeneticVariation | group | BEFREE | STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. | 20028972 | 2010 |